We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

84 hedge funds and large institutions have $330M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

24% more funds holding

Funds holding: 68 → 84 (+16)

4% more capital invested

Capital invested by funds: $316M → $330M (+$14.1M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
84
Holders Change
+16
Holders Change %
+23.53%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
33
Increased
27
Reduced
12
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$26.7M
2
State Street
State Street
Massachusetts
+$14.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.6M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.81M
5
Northern Trust
Northern Trust
Illinois
+$3.89M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$4.99M
2
Millennium Management
Millennium Management
New York
-$4.69M
3
FFM
Fairmount Funds Management
Pennsylvania
-$3.66M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.58M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
26
Polar Asset Management Partners
Ontario, Canada
$1.38M +$1.55M +203,000 New
Charles Schwab
27
Charles Schwab
California
$1.31M +$1.25M +162,711 +560%
Invesco
28
Invesco
Georgia
$1.26M +$1.42M +185,090 New
BFS
29
Baskin Financial Services
Ontario, Canada
$1.22M – – –
OIM
30
Oracle Investment Management
Connecticut
$884K +$993K +129,810 New
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$659K -$2.58M -337,256 -78%
Swiss National Bank
32
Swiss National Bank
Switzerland
$651K +$79.6K +10,400 +12%
Bank of America
33
Bank of America
North Carolina
$605K -$175K -22,825 -20%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$588K +$660K +86,278 New
Morgan Stanley
35
Morgan Stanley
New York
$521K +$474K +61,942 +420%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$452K +$244K +31,844 +92%
Citigroup
37
Citigroup
New York
$430K +$386K +50,477 +398%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$396K +$445K +58,210 New
AA
39
ALPS Advisors
Colorado
$378K +$425K +55,480 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$352K +$396K +51,700 New
Deutsche Bank
41
Deutsche Bank
Germany
$286K +$321K +41,990 New
MIM
42
MetLife Investment Management
New Jersey
$279K +$313K +40,935 New
FWP
43
Firethorn Wealth Partners
Georgia
$271K +$26.6K +3,480 +10%
JP Morgan Chase
44
JP Morgan Chase
New York
$271K +$150K +19,616 +97%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$270K +$74.9K +9,783 +33%
AIG
46
American International Group
New York
$236K +$265K +34,661 New
UBS AM
47
UBS AM
Illinois
$227K +$116K +15,100 +83%
TI
48
Trexquant Investment
Connecticut
$226K +$254K +33,244 New
Fidelity Investments
49
Fidelity Investments
Massachusetts
$212K +$238K +31,066 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$205K +$231K +30,149 New
1
2
3 4 5

PNT Hedge Fund Activity: Q2 2022 in Review

84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q2 2022, worth a combined $330M — up 4.5% from $316M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PNT positions and 17 closed out — a net gain of 16 holders — while 27 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $26.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $4.99M sold.

  • 84 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q2 2022, up from 68 in Q1 2022.
  • Funds reported $330M of POINT Biopharma Global Inc. Common Stock stock for Q2 2022, up 4.5% quarter-over-quarter.
  • 33 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q2 2022 and 17 closed out, a net change of +16 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q2 2022 was BlackRock, an estimated $26.7M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q2 2022 was Farallon Capital Management, an estimated $4.99M sold.

Based on aggregated 13F filings for Q2 2022.